BiBBInstruments announces final outcome of rights issue
BiBBInstruments AB (“BiBB” or the “Company”) today announces the final outcome of the rights issue of units of approximately SEK 36.5 million that was announced by the Company on 8 November...
BiBBInstruments announces preliminary outcome of rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA,...
Clinical evaluation at Karolinska University Hospital is progressing
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of EndoDrill®, the world’s first market-cleared, electric-driven biopsy instrument for endoscopy, announces that the Company’s clinical evaluation is proceeding...
Well-executed clinical introduction of EndoDrill® GI at Sahlgrenska University Hospital in Sweden
The cancer diagnostics company BiBBInstruments AB (“BiBB” and the “Company”), the developer of EndoDrill®, the world’s first market-cleared electric-driven biopsy instrument for endoscopy, announces that the first clinical tissue sampling procedures...
BiBB has initiated a collaboration with Swedish contract manufacturer Cenova
The cancer diagnostics company BiBBInstruments AB (“BiBB” and the “Company”), the developer of EndoDrill®, the world’s first market-cleared electric-driven biopsy instrument for endoscopy, informs that the Company has initiated a collaboration...
Impressive US Clinical Case Series presented at ACG 2024 in Philadelphia
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, announces that a recently published clinical case series in...
BiBB receives an Intention to Grant for EndoDrill patent in China
The cancer diagnostics company BiBBInstruments AB (“BiBB”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, today announces that the Company has received an Intention to Grant from...
New Peer-Reviewed Clinical Case Series in the U.S. Shows 100% Diagnostic Accuracy with EndoDrill GI
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, announces that the first eight patient cases using EndoDrill®...
EndoDrill GI sparks interest at the 7th Nordic EUS Meeting in Copenhagen
The cancer diagnostics company BiBBInstruments AB (“BiBB or the “Company”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, announces that the Company, for the first time, has...
BiBB receives an Intention to Grant for EndoDrill patent in Europe
The cancer diagnostics company BiBBInstruments AB (“BiBB”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, today announces that the Company has received an Intention to Grant from...
Successful introduction of EndoDrill GI at University Hospital Center Sestre Milosrdnice in Zagreb, Croatia
The cancer diagnostics company BiBBInstruments AB (“BiBB”), the developer of the world’s first market-cleared electric-driven biopsy instrument for endoscopy, announces that the University Hospital Center Sestre Milosrdnice in Zagreb, Croatia, has...
EndoDrill is recognized as a promising new product for solving a significant clinical problem in a medical journal
The cancer diagnostics company BiBBInstruments AB (“BiBB”), the developer of EndoDrill®, the world’s first market-cleared motorized endoscopic core biopsy instrument, informs that EndoDrill® is recognized as a promising new EUS product...